These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 25868018)

  • 1. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon.
    Kuaban C; Noeske J; Rieder HL; Aït-Khaled N; Abena Foe JL; Trébucq A
    Int J Tuberc Lung Dis; 2015 May; 19(5):517-24. PubMed ID: 25868018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses.
    Piubello A; Harouna SH; Souleymane MB; Boukary I; Morou S; Daouda M; Hanki Y; Van Deun A
    Int J Tuberc Lung Dis; 2014 Oct; 18(10):1188-94. PubMed ID: 25216832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients.
    Aung KJ; Van Deun A; Declercq E; Sarker MR; Das PK; Hossain MA; Rieder HL
    Int J Tuberc Lung Dis; 2014 Oct; 18(10):1180-7. PubMed ID: 25216831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of a standardised regimen for multidrug-resistant tuberculosis in Bangladesh.
    Van Deun A; Salim MA; Das AP; Bastian I; Portaels F
    Int J Tuberc Lung Dis; 2004 May; 8(5):560-7. PubMed ID: 15137531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial resistance to companion drugs should not be considered an exclusion criterion for the shorter multidrug-resistant tuberculosis treatment regimen.
    Lempens P; Decroo T; Aung KJM; Hossain MA; Rigouts L; Meehan CJ; Van Deun A; de Jong BC
    Int J Infect Dis; 2020 Nov; 100():357-365. PubMed ID: 32829049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequency of recurrence among MDR-tB cases 'successfully' treated with standardised short-course chemotherapy.
    Migliori GB; Espinal M; Danilova ID; Punga VV; Grzemska M; Raviglione MC
    Int J Tuberc Lung Dis; 2002 Oct; 6(10):858-64. PubMed ID: 12365571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment outcome with a short multidrug-resistant tuberculosis regimen in nine African countries.
    Trébucq A; Schwoebel V; Kashongwe Z; Bakayoko A; Kuaban C; Noeske J; Hassane S; Souleymane B; Piubello A; Ciza F; Fikouma V; Gasana M; Ouedraogo M; Gninafon M; Van Deun A; Cirillo DM; Koura KG; Rieder HL
    Int J Tuberc Lung Dis; 2018 Jan; 22(1):17-25. PubMed ID: 29149917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Applicability of the shorter 'Bangladesh regimen' in high multidrug-resistant tuberculosis settings.
    Sotgiu G; Tiberi S; Centis R; D'Ambrosio L; Fuentes Z; Zumla A; Migliori GB
    Int J Infect Dis; 2017 Mar; 56():190-193. PubMed ID: 27816662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-course treatment outcomes and adverse events in adults and children-adolescents with MDR-TB in Niger.
    Harouna SH; Ortuno-Gutierrez N; Souleymane MB; Kizito W; Morou S; Boukary I; Zolfo M; Benedetti G; Piubello A
    Int J Tuberc Lung Dis; 2019 May; 23(5):625-630. PubMed ID: 31097073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis.
    Park S; Jo KW; Lee SD; Kim WS; Shim TS
    Respir Med; 2017 Oct; 131():43-48. PubMed ID: 28947041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose gatifloxacin-based shorter treatment regimens for MDR/RR-TB.
    Nie Q; Tao L; Li Y; Chen N; Chen H; Zhou Y; Wang Y; Chen H; Tang Q; Wang X; Huang C; Yang C
    Int J Infect Dis; 2022 Feb; 115():142-148. PubMed ID: 34861398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of a 12-month regimen for drug-resistant pulmonary tuberculosis.
    Pérez-Guzmán C; Vargas MH; Martínez-Rossier LA; Torres-Cruz A; Villarreal-Velarde H
    Int J Tuberc Lung Dis; 2002 Dec; 6(12):1102-9. PubMed ID: 12546119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Revised Category II regimen as an alternative strategy for retreatment of Category I regimen failure and irregular treatment cases.
    Tabarsi P; Chitsaz E; Tabatabaei V; Baghaei P; Shamaei M; Farnia P; Marjani M; Kazempour M; Mansouri D; Masjedi MR; Velayati AA
    Am J Ther; 2011 Sep; 18(5):343-9. PubMed ID: 20535008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
    Park SK; Kim JH; Kang H; Cho JS; Smego RA
    Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potentially High Number of Ineffective Drugs with the Standard Shorter Course Regimen for Multidrug-Resistant Tuberculosis Treatment in Haiti.
    Walsh KF; Souroutzidis A; Vilbrun SC; Peeples M; Joissaint G; Delva S; Widmann P; Royal G; Pry J; Bang H; Pape JW; Koenig SP
    Am J Trop Med Hyg; 2019 Feb; 100(2):392-398. PubMed ID: 30594266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
    Centers for Disease Control and Prevention
    MMWR Recomm Rep; 2013 Oct; 62(RR-09):1-12. PubMed ID: 24157696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment outcomes of multidrug-resistant tuberculosis--comparison between success and failure cases].
    Shigetoh E; Murakami I; Yokosaki Y; Kurimoto N
    Kekkaku; 2001 Dec; 76(12):723-8. PubMed ID: 11806128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months.
    Nolan CM; Goldberg SV
    Int J Tuberc Lung Dis; 2002 Nov; 6(11):952-8. PubMed ID: 12475140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of Shorter Treatment Regimen in Multidrug-Resistant Tuberculosis Patients in Pakistan: A Multicenter Retrospective Record Review.
    Wahid A; Ahmad N; Ghafoor A; Latif A; Saleem F; Khan S; Atif M; Iqbal Q
    Am J Trop Med Hyg; 2021 Mar; 104(5):1784-1791. PubMed ID: 33724924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.